InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector
April 21 2022 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a leader in the research, development,
manufacturing and commercialization of rare cannabinoids, is
pleased to announce it has launched B2B sales of the rare
cannabinoid cannabidivarin (“CBDV”) to wholesalers, suppliers and
end-product manufacturers in the health and wellness sector through
its US subsidiary, BayMedica LLC.
“Ensuring a reliable, large volume source of
highly pure, bioidentical CBDV is an important step forward in the
health and wellness sector. CBDV has been researched for its
therapeutic potential in several disease areas such as autism
spectrum disorder,” said Shane Johnson, MD, SVP and General Manager
of BayMedica. “Whether you are a researcher or product developer at
a multinational consumer package goods (‘CPG’) company, the ability
to access highly pure and consistent active ingredients, free from
contaminants typically found in plant-sourced cannabinoids such as
pesticides, heavy metals, or potentially even THC, is a fundamental
requirement. BayMedica’s cannabinoid manufacturing technologies
provides exactly that value and we are excited to continue to
introduce to the market additional rare cannabinoids that have
previously not been abundantly accessible, including adding THCV to
our portfolio in the immediate future.”
CBDV – An important twist on
CBDCBDV is a non-intoxicating rare cannabinoid that has a
similar molecular structure to CBD but with two fewer carbon atoms
on its sidechain, resulting in important differences in activity.
The BayMedica team has curated a collection of scientific research
studies on the physiological and potential therapeutic properties
of CBDV. CBDV is one of the most studied rare cannabinoids and has
been the subject of research in autism, epilepsy, acne, alopecia,
inflammatory bowel disease, nausea, and pain. CBDV is also
currently being studied in a number of clinical trials including
autism, Prader-Willi Syndrome, and attention deficit hyperactivity
disorder (ADHD). Click here to download the white paper.
BayMedica – We do cannabinoids
differentlyBayMedica manufactures rare cannabinoids
through novel synthetic methods that ensure reproducible quality
and purity. The Company’s products are manufactured under
food-grade GMP (Good Manufacturing Practice) standards for the
health and wellness sector, and are bioidentical to plant-derived
compounds. These cannabinoids can be custom formulated for a
variety of consumer health and wellness applications including
supplements, nutraceuticals, cosmetics and animal health. Utilizing
reproducible processes guarantee the purity and consistency of our
cannabinoids each and every time. Furthermore, these production
methods can be scaled up to meet demand to ensure that clients have
an ongoing source of cannabinoids without supply chain
concerns.
Increasing demand for rare
cannabinoidsAs research continues to identify the unique
characteristics of cannabinoids beyond THC and CBD, the use and
acceptance of all cannabinoids is poised to grow significantly over
the coming months and years. Key indicators that point to
significant growth include online analytics, emerging trends in the
regulated hemp and marijuana sectors, and R&D among
multinational CPGs. Reports such as the December 2021 Grand View
Research report, that predicts the retail market for rare
cannabinoids will reach US$26 Billion by 2028, adds to the growing
body of data.
By establishing a reliable supply of these rare
cannabinoids at commercial scale, innovative product manufacturers
and consumer brands now have the ability to deliver improved and
differentiated products via product line extensions and
formulations designed to increase the performance of their
products.
For more information on how to purchase CBDV and
other rare cannabinoids, please reach out to the BayMedica sales
team at: orders@baymedica.com
Learn more about BayMedica’s products:Minor
Cannabinoids CBC CBDV THCV CBT | BayMedica
About InMed: InMed
Pharmaceuticals is a global leader in the research, development,
manufacturing and commercialization of rare cannabinoids. Together
with its subsidiary BayMedica LLC, the Company has unparalleled
cannabinoid manufacturing capabilities to serve a spectrum of
consumer markets, including pharmaceutical and health and wellness.
InMed is also a clinical-stage company developing a pipeline of
rare cannabinoid therapeutics and dedicated to delivering new
treatment alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com and www.baymedica.com.
Investor Contact: Colin ClancySenior Director,
Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking
Information:
This news release contains “forward-looking
information” and “forward-looking statements” (collectively,
“forward-looking information”) within the meaning of applicable
securities laws. Forward-looking information is based on
management’s current expectations and beliefs and is subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Forward-looking information in this news release
includes statements about: launching B2B sales of CBDV into the
health and wellness sector; ensuring a reliable, large volume
source of CBDV; BayMedica’s manufacturing technologies providing
value; launching additional rare cannabinoids, including THCV in
the immediate future; CBDV having important differences from CBD in
terms of activity; the potential for rare cannabinoids to treat
various diseases; the use and acceptance of all cannabinoids being
poised to grow significantly over the coming months and years;
being a global leader in the research, development, manufacturing
and development of rare cannabinoids; and delivering new treatment
alternatives to patients that may benefit from cannabinoid-based
pharmaceutical drugs.
With respect to the forward-looking information
contained in this news release, InMed has made numerous
assumptions. While InMed considers these assumptions to be
reasonable, these assumptions are inherently subject to significant
business, economic, competitive, market and social uncertainties
and contingencies.
Additionally, there are known and unknown risk
factors which could cause InMed’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. A complete discussion
of the risks and uncertainties facing InMed’s stand-alone business
is disclosed in InMed’s Annual Report on Form 10-K and other
filings with the Security and Exchange Commission on
www.sec.gov.
All forward-looking information herein is
qualified in its entirety by this cautionary statement, and InMed
disclaims any obligation to revise or update any such
forward-looking information or to publicly announce the result of
any revisions to any of the forward-looking information contained
herein to reflect future results, events or developments, except as
required by law.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024